Full-Time
Manager HR Knowledge Management
Posted on 11/23/2025
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 People & HR (1) |
|---|
- 8-12 years of progressive experience in HR, knowledge management, digital HR, HR service delivery roles or equivalent experience
- Demonstrated success in leading enterprise-level knowledge management initiatives or digital transformation programs.
- Expertise in knowledge platforms (e.g., ServiceNow, SharePoint) and content governance methodologies.
- Understanding of HR operating models, shared services, and employee experience principles.
- Stakeholder management, communication, and facilitation skills.
- Analytical and strategic thinker with a track record of using data to drive decisions and improvements.
- Proven ability to manage projects in a dynamic environment.
- Lead a team of knowledge management (Sr) associates to implement global HR knowledge management strategy, ensuring alignment with business goals, employee experience, and digital HR transformation.
- Establish and enforce enterprise-wide content governance frameworks, including lifecycle management, compliance controls, and quality assurance standards.
- Champion consistency in tone, structure, and branding across all HR knowledge and HR Service delivery assets, ensuring alignment with corporate goals.
- Act as liaison between HR Centers of Expertise (CoE), HRBPs, and Local HR Operations to ensure timely, accurate, and relevant knowledge delivery.
- Enable business continuity across HR knowledge & HR service delivery platforms (e.g., ServiceNow Knowledge Base, SharePoint), driving platform evolution and innovation.
- Drive continuous optimization of taxonomy, metadata, and search architecture to enhance discoverability and user experience.
- Partner with Digital Technology and HRIS teams to prioritize and deliver platform enhancements and automation opportunities.
- Design and deliver enablement programs for content contributors, HR teams, and end-users to build capability and drive adoption.
- Lead communication campaigns to promote knowledge tools, self-service behaviors, and digital HR initiatives.
- Foster a culture of knowledge sharing, collaboration, and continuous learning across the HR organization.
- Lead HR service delivery projects such as HR portal optimization, AI-enabled knowledge delivery, and global content harmonization.
- Manage project timelines, resources, risks, and stakeholder communications to ensure successful delivery and measurable impact.
- Continuously scan for emerging trends and technologies in knowledge management and digital HR to inform future strategy
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Simplify's Take
What believers are saying
- Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
- Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
- Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.
What critics are saying
- Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
- FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
- Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.
What makes Amgen unique
- Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
- MariTide advances in Phase III obesity trials with monthly dosing.
- UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.
Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.
Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.
Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.